Pricing strategies for combination pediatric vaccines based on the lowest overall cost formulary.

Banafsheh Behzad; Sheldon H. Jacobson; Edward C. Sewell

doi:10.1586/erv.12.97

Pricing strategies for combination pediatric vaccines based on the lowest overall cost formulary.

Banafsheh Behzad, Sheldon H. Jacobson, Edward C. Sewell

Research output: Contribution to journal › Article › peer-review

Abstract

This paper analyzes pricing strategies for US pediatric combination vaccines by comparing the lowest overall cost formularies (i.e., formularies that have the lowest overall cost). Three pharmaceutical companies compete pairwise over the sale of monovalent and combination vaccines. Particular emphasis is placed on examining the price of Sanofi Pasteur's DTaP-IPV/HIb under different conditions. The main contribution of the paper is to provide the lowest overall cost formularies for different prices of DTaP-IPV/HIb and other Sanofi Pasteur vaccines. The resulting analysis shows that DTaP-IPV/HIb could have been more competitively priced compared with the combination vaccine DTaP-HepB-IPV, for federal contract prices in 2009, 2010 and 2011. This study also proposes the lowest overall cost formularies when shortages of monovalent vaccines occur.

Original language	English (US)
Pages (from-to)	1189-1197
Number of pages	9
Journal	Expert review of vaccines
Volume	11
Issue number	10
DOIs	https://doi.org/10.1586/erv.12.97
State	Published - Oct 2012
Externally published	Yes

ASJC Scopus subject areas

Immunology
Molecular Medicine
Pharmacology
Drug Discovery

Online availability

10.1586/erv.12.97

Library availability

Discover UIUC Full Text

Cite this

@article{21135b4431d946de9fe6f11d1e1e1540,

title = "Pricing strategies for combination pediatric vaccines based on the lowest overall cost formulary.",

abstract = "This paper analyzes pricing strategies for US pediatric combination vaccines by comparing the lowest overall cost formularies (i.e., formularies that have the lowest overall cost). Three pharmaceutical companies compete pairwise over the sale of monovalent and combination vaccines. Particular emphasis is placed on examining the price of Sanofi Pasteur's DTaP-IPV/HIb under different conditions. The main contribution of the paper is to provide the lowest overall cost formularies for different prices of DTaP-IPV/HIb and other Sanofi Pasteur vaccines. The resulting analysis shows that DTaP-IPV/HIb could have been more competitively priced compared with the combination vaccine DTaP-HepB-IPV, for federal contract prices in 2009, 2010 and 2011. This study also proposes the lowest overall cost formularies when shortages of monovalent vaccines occur.",

author = "Banafsheh Behzad and Jacobson, {Sheldon H.} and Sewell, {Edward C.}",

note = "Funding Information: This research has been supported in part by the National Science Foundation (CMMI-1161458). SH Jacobson was also supported in part by the Air Force Office of Scientific Research (FA9550-10-1-0387). This material is based upon work supported in part by (while serving at) the National Science Foundation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Copyright: This record is sourced from MEDLINE{\textregistered}/PubMed{\textregistered}, a database of the U.S. National Library of Medicine",

year = "2012",

month = oct,

doi = "10.1586/erv.12.97",

language = "English (US)",

volume = "11",

pages = "1189--1197",

journal = "Expert review of vaccines",

issn = "1476-0584",

publisher = "Taylor and Francis Ltd.",

number = "10",

}

TY - JOUR

T1 - Pricing strategies for combination pediatric vaccines based on the lowest overall cost formulary.

AU - Behzad, Banafsheh

AU - Jacobson, Sheldon H.

AU - Sewell, Edward C.

N1 - Funding Information: This research has been supported in part by the National Science Foundation (CMMI-1161458). SH Jacobson was also supported in part by the Air Force Office of Scientific Research (FA9550-10-1-0387). This material is based upon work supported in part by (while serving at) the National Science Foundation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Copyright: This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

PY - 2012/10

Y1 - 2012/10

N2 - This paper analyzes pricing strategies for US pediatric combination vaccines by comparing the lowest overall cost formularies (i.e., formularies that have the lowest overall cost). Three pharmaceutical companies compete pairwise over the sale of monovalent and combination vaccines. Particular emphasis is placed on examining the price of Sanofi Pasteur's DTaP-IPV/HIb under different conditions. The main contribution of the paper is to provide the lowest overall cost formularies for different prices of DTaP-IPV/HIb and other Sanofi Pasteur vaccines. The resulting analysis shows that DTaP-IPV/HIb could have been more competitively priced compared with the combination vaccine DTaP-HepB-IPV, for federal contract prices in 2009, 2010 and 2011. This study also proposes the lowest overall cost formularies when shortages of monovalent vaccines occur.

AB - This paper analyzes pricing strategies for US pediatric combination vaccines by comparing the lowest overall cost formularies (i.e., formularies that have the lowest overall cost). Three pharmaceutical companies compete pairwise over the sale of monovalent and combination vaccines. Particular emphasis is placed on examining the price of Sanofi Pasteur's DTaP-IPV/HIb under different conditions. The main contribution of the paper is to provide the lowest overall cost formularies for different prices of DTaP-IPV/HIb and other Sanofi Pasteur vaccines. The resulting analysis shows that DTaP-IPV/HIb could have been more competitively priced compared with the combination vaccine DTaP-HepB-IPV, for federal contract prices in 2009, 2010 and 2011. This study also proposes the lowest overall cost formularies when shortages of monovalent vaccines occur.

UR - http://www.scopus.com/inward/record.url?scp=84876429582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876429582&partnerID=8YFLogxK

U2 - 10.1586/erv.12.97

DO - 10.1586/erv.12.97

M3 - Article

C2 - 23176652

AN - SCOPUS:84876429582

SN - 1476-0584

VL - 11

SP - 1189

EP - 1197

JO - Expert review of vaccines

JF - Expert review of vaccines

IS - 10

ER -

Pricing strategies for combination pediatric vaccines based on the lowest overall cost formulary.

Abstract

ASJC Scopus subject areas

Online availability

Library availability

Related links

Fingerprint

Cite this